Adimmune Corporation (TWSE:4142) today announced that three of its vaccines—the seasonal influenza vaccine, tetanus toxoid vaccine, and the enterovirus 71 (EV71) vaccine developed by its subsidiary Enimmune—are now officially listed in the World Health Organization (WHO) Full Vaccine Product List published in September. Inclusion in the WHO list signifies that Adimmune has entered the global public health supply chain, marking a significant milestone for Taiwan’s vaccine industry as its quality and manufacturing capabilities gain recognition from the global health community.   

The WHO’s latest Full Vaccine Product List includes more than 1,000 vaccines available for procurement worldwide. The purpose of the list is to enhance transparency in vaccine demand, supply capacity, and price fluctuations, thereby helping countries assess affordability and potential shortage risks. By strengthening national and regional capabilities, the initiative aims to improve global vaccine accessibility and advance WHO’s goals of promoting public health and increasing immunization coverage.   

Adimmune stated that being listed by WHO demonstrates meaningful progress for Taiwan in the global vaccine market and will accelerate the company’s international expansion efforts. Currently, Adimmune supplies nearly 50 percent of Taiwan’s annual government-funded seasonal influenza vaccines, and also exports to Southeast Asia and Eastern Europe. It has recently completed Brazilian GMP inspection and is progressing toward regulatory approval in Brazil to enter the South American market. Adimmune’s tetanus toxoid vaccine is the only domestically licensed tetanus vaccine in Taiwan, supplying over one million doses per year. The company is also preparing to introduce a new single-dose tetanus syringe by the end of the year to better support emergency clinical use.   

The EV71 enterovirus vaccine, listed by WHO for future procurement reference, obtained marketing authorization in Taiwan in 2023. In 2025, its Phase III clinical study results demonstrated 99.21% protective efficacy. The product is actively seeking access into Southeast Asia, with regulatory submissions underway in Macau, Vietnam, and Thailand, and a distribution agreement already signed with ETANA, Indonesia’s largest private biopharmaceutical company. WHO listing is expected to accelerate the vaccine’s international availability.   

Although Taiwan is not a WHO member state, Adimmune signed an SMTA2 agreement with WHO in 2024. The agreement ensures that Adimmune will receive priority access to influenza biological materials in the event of an outbreak, enabling rapid development of new flu vaccines or antiviral treatments. This collaboration demonstrates Adimmune’s commitment not only to Taiwan’s health security but also to global pandemic preparedness.   

To align with international development, Adimmune joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) Influenza Vaccine Supply International Task Force (IVS) as early as 2012, becoming an industry partner alongside global leaders such as Sanofi and GSK. Adimmune is also the only Taiwan-based vaccine manufacturer participating in WHO’s Pandemic Influenza Preparedness (PIP) Framework.